InsiderSignal.AI

InsiderSignal.ai

SMMT - Summit Therapeutics Inc.

Insider Purchase by Xia Yu (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Xia Yu, serving as Dir at Summit Therapeutics Inc. (SMMT), purchased 533,617 shares at $18.74 per share, for a total transaction value of $9,999,983.00. Following this transaction, Xia Yu now holds 32,057,147 shares of SMMT.

This purchase represents a 2.00% increase in Xia Yu's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, October 21, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 23, 2025, 2 days after the trade was made.

Summit Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Xia Yu

Dir

Xia Yu (Michelle Xia) is a prominent Chinese biopharmaceutical executive who founded Akeso, Inc. in 2012 and has served as its chairwoman, president, and chief executive officer since inception.[[1]](https://en.wikipedia.org/wiki/Michelle_Xia)[[5]](https://www.marketscreener.com/insider/MICHELLE-XIA-A29M5F/) Born in Gansu province to university-educated engineer parents, she earned a biochemistry degree from Sun Yat-sen University in 1988 and a doctorate in molecular biology and microbiology from Newcastle University, UK, followed by postgraduate studies at the University of Glasgow.[[1]](https://en.wikipedia.org/wiki/Michelle_Xia) Early in her career, she conducted cancer research at the University of Louisville in the US and held scientific and leadership roles at Crown Bioscience, PDL BioPharma, and Bayer.[[1]](https://en.wikipedia.org/wiki/Michelle_Xia) Since 2023, Xia Yu has served as a Director on the board of Summit Therapeutics Inc. (SMMT), where she has been involved as a corporate insider with reported ownership and trading activity.[[2]](https://www.gurufocus.com/insider/226524/yu-xia)[[3]](https://www.forbes.com.au/news/billionaires/this-immigrant-just-became-a-biotech-billionaire/)[[4]](https://stockcircle.com/insider-trades/person/xia-yu) Under her leadership at Akeso, the company developed ivonescimab, licensed to Summit in 2022, which has shown promising results outperforming Merck's Keytruda in clinical trials for non-small cell lung cancer.[[1]](https://en.wikipedia.org/wiki/Michelle_Xia)[[3]](https://www.forbes.com.au/news/billionaires/this-immigrant-just-became-a-biotech-billionaire/) Recognized in TIME100 Health in 2025 and with a net worth estimated at $1.2 billion as of July 2025, she continues to drive innovation in oncology therapeutics.[[1]](https://en.wikipedia.org/wiki/Michelle_Xia)

View full insider profile →

Trade Price

$18.74

Quantity

533,617

Total Value

$9,999,983.00

Shares Owned

32,057,147

Trade Date

Tuesday, October 21, 2025

124 days ago

SEC Filing Date

Thursday, October 23, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Summit Therapeutics Inc.

Company Overview

No company information available
View news mentioning SMMT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/894620

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime